Nocturnal polyuria, a key contributing factor of nocturia in adults, is characterized by overproduction of urine at night. Changes in lifestyle and circadian rhythms, and conditions such as hormonal imbalance, congestive heart failure, nephrotic disorders, and obstructive sleep apnea are common causes of nocturnal polyuria. The primary objective of disease treatment is to curb urine production at night. Physicians manage the disease with lifestyle modifications initially before moving to pharmacotherapy. Desmopressin, branded as Noctiva (nasal spray) and Nocdurna (sublingual), are the only FDA-approved drugs currently available for nocturnal polyuria, though physicians also use midafternoon diuretics and tricyclic antidepressants to treat the condition. Importantly, desmopressin has a black box warning for hyponatremia, which further limits physicians’ options for disease management, providing market opportunity for agents to enter this space.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed nocturnal polyuria patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed patients?
  • How have Noctiva and Nocdurna been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of nocturnal polyuria patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of nocturnal polyuria patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Nocturnal Polyuria - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US)
    • Treatment Algorithms:Claims Data Analysis:Nocturnal Polyuria-US-September-2020

Author(s): Mohit Nasa, M.B.A.

Mohit Nasa, M.B.A., is a principal analyst on the Immune and Inflammatory Disorders team at DRG, part of Clarivate. He has authored content on such indications as systemic lupus erythropoiesis, psoriasis, asthma, and rheumatoid arthritis. Prior to joining DRG, he worked as a senior business analyst at Novartis, where he was responsible for end-to-end market assessment and related projects for Novartis’s asthma brand Xolair. Mr. Nasa holds a bachelor’s degree in pharmacy and an M.B.A. in marketing and CRM from Amity Business School in India.